Simulations Plus, Inc. filings document a California operating company that reports as a provider of model-informed and AI-accelerated drug development software and services. Its 8-K reports furnish quarterly financial results, investor presentation materials, preliminary operating updates, guidance-related disclosures, and Regulation FD information tied to its software and services business.
The company’s proxy and governance filings cover annual meeting voting, director and executive compensation matters, shareholder approval of amendments to the 2021 Equity Incentive Plan, and common-stock authorization for equity awards. Other material-event reports document executive employment agreements, changes in the independent registered public accounting firm, internal-control and segment-reporting matters, and related audit committee actions.
Simulations Plus director Lisa LaVange reported the sale of 867 shares of the company's common stock on 09/02/2025. The Form 4 states the shares were sold in a single transaction at $14.10 per share and that the sale was effected automatically pursuant to a Rule 10b5-1 trading plan. Following the reported transaction, Ms. LaVange beneficially owns 9,063 shares and holds those shares in a direct ownership form. The filing indicates the reporter is a director and the Form 4 was executed by an attorney-in-fact on 09/04/2025.